GLMD Stock Analysis: Buy, Sell, or Hold?
GLMD - Galmed Pharmaceuticals Ltd.
$4.31
-0.25 (-5.59%)
▼
5d:
+722.98%
30d:
+678.48%
90d:
+642.11%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 27, 2026
2d
Get Alerted When GLMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: GLMD is 642.2% above its trading range ($0.58). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: GLMD is 642.2% above its trading range ($0.58). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: GLMD is currently trading at $4.30, which is considered slightly low relative to its 30-day fair value range of $0.52 to $0.58.
Technical Outlook: Technically, GLMD is showing sideways momentum. Immediate support is located at $0.50, while resistance sits at $5.45. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: GLMD scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+178.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLMD is showing sideways momentum. Immediate support is located at $0.50, while resistance sits at $5.45. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: GLMD scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+178.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.52 -
$0.58
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 178.7% below Wall St target ($12.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.52 -
$0.58
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.50
Resistance Level
$5.45
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.60
Wall Street Target
$12.00
(+178.7%)
Share & Embed Analysis
Last updated: August 24, 2026 9:46 AM ET
Data refreshes hourly during market hours. Next update: 10:46 AM
Data refreshes hourly during market hours. Next update: 10:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
